BR112012012085A2 - compostos antivirais heterocíclicos - Google Patents

compostos antivirais heterocíclicos

Info

Publication number
BR112012012085A2
BR112012012085A2 BR112012012085A BR112012012085A BR112012012085A2 BR 112012012085 A2 BR112012012085 A2 BR 112012012085A2 BR 112012012085 A BR112012012085 A BR 112012012085A BR 112012012085 A BR112012012085 A BR 112012012085A BR 112012012085 A2 BR112012012085 A2 BR 112012012085A2
Authority
BR
Brazil
Prior art keywords
antiviral compounds
heterocyclic antiviral
compounds
disclosed
heterocyclic
Prior art date
Application number
BR112012012085A
Other languages
English (en)
Inventor
Joshua Paul Gergely Taygerly
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012012085A2 publication Critical patent/BR112012012085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

compostos antivirais heterocíclicos. expõem-se compostos que são dotados da fórmula i, emque r^ 1^, r^ 2^, r^ 3^ são tais como definidos neste contexto os quais são inibidores de polimerase ns5b de vírus da hepatite c com bio-disponibilidade aperfeiçoada. expôem-se igualmente as composições e métodos para o tratamento de uma infecção por hcv e inibição de replicação de hcv.
BR112012012085A 2009-11-21 2010-11-18 compostos antivirais heterocíclicos BR112012012085A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26335009P 2009-11-21 2009-11-21
PCT/EP2010/067718 WO2011061243A1 (en) 2009-11-21 2010-11-18 Heterocyclic antiviral compounds

Publications (1)

Publication Number Publication Date
BR112012012085A2 true BR112012012085A2 (pt) 2016-05-17

Family

ID=43446565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012085A BR112012012085A2 (pt) 2009-11-21 2010-11-18 compostos antivirais heterocíclicos

Country Status (11)

Country Link
US (1) US8383824B2 (pt)
EP (1) EP2501679A1 (pt)
JP (1) JP2013511489A (pt)
KR (1) KR20120085918A (pt)
CN (1) CN102639504A (pt)
AR (1) AR079076A1 (pt)
BR (1) BR112012012085A2 (pt)
CA (1) CA2778206A1 (pt)
MX (1) MX2012005706A (pt)
TW (1) TW201129362A (pt)
WO (1) WO2011061243A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014217907B4 (de) 2014-09-08 2018-12-20 Carl Zeiss Smt Gmbh Verfahren zum Herstellen einer Maske für den extrem ultra-violetten Wellenlängenbereich und Maske
US9765050B2 (en) 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
DE60034027T2 (de) 1999-12-24 2007-12-13 Asahi Glass Co., Ltd. Siliziumnitridfilter und verfahren zu dessen herstellung
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
AU2002359320A1 (en) 2001-10-29 2003-05-12 Smithkline Beecham Corporation Novel anit-infectives
WO2003059356A2 (en) 2001-10-30 2003-07-24 Smithkline Beecham Corporation Novel anti-infectives
AP1789A (en) * 2002-04-08 2007-10-05 Pfizer Tropane derivatives useful in therapy.
WO2003099801A1 (en) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
EP1515978A1 (en) * 2002-06-20 2005-03-23 IC Vec Limited Sulfur-containing phospholipid derivatives
KR20050065670A (ko) 2002-11-01 2005-06-29 아보트 러보러터리즈 항감염제
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004052312A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
WO2004052313A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
AU2003297235A1 (en) 2002-12-17 2004-07-22 Smithkline Beecham Corporation Anti-infectives
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
RU2007110531A (ru) 2004-08-23 2008-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические противовирусные соединения
MX2007013415A (es) 2005-05-04 2008-01-15 Hoffmann La Roche Compuestos antivirales heterociclicos.
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
PE20090630A1 (es) * 2007-08-29 2009-05-16 Schering Corp Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PT2203430E (pt) * 2007-09-17 2011-09-02 Abbott Lab N-fenildioxohidropirimidinas úteis como inibidores do vírus da hepatite c (vhc)
CN104628655A (zh) * 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CA2699981C (en) * 2007-09-17 2017-08-22 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
CA2709348C (en) 2007-12-21 2016-07-19 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors for treating human immunodeficiency virus (hiv-1) mediated diseases
BRPI0916233A2 (pt) * 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais
AU2009331660A1 (en) * 2008-12-22 2011-06-30 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2411352B1 (en) * 2009-03-25 2017-01-18 AbbVie Inc. Antiviral compounds and uses thereof

Also Published As

Publication number Publication date
US20110123489A1 (en) 2011-05-26
JP2013511489A (ja) 2013-04-04
CA2778206A1 (en) 2011-05-26
AR079076A1 (es) 2011-12-21
TW201129362A (en) 2011-09-01
EP2501679A1 (en) 2012-09-26
KR20120085918A (ko) 2012-08-01
MX2012005706A (es) 2012-06-12
CN102639504A (zh) 2012-08-15
US8383824B2 (en) 2013-02-26
WO2011061243A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
BR112012015951A2 (pt) 4 azido-nucleosídeos como compostos anti-hcv
MX2012003170A (es) Compuestos heterociclicos antivirales.
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
MX2010004623A (es) Compuestos heterociclicos antiviricos.
BR112012014299A2 (pt) composto de antivírus heterocíclicos
ECSP088518A (es) Nucleósidos antivirales
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
CL2013002299A1 (es) Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011).
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
CR20110605A (es) Compuestos heterocíclicos antivirales
CO6300958A2 (es) Nucleosidos de imidazol[1,5-f][1,2,4]triazinil, imidazol[1,2-f]1,2,4]triazinil y [1,2,4]triazolo[4,3-f][1,2,4]triazinil para tratamiento antiviral.
UY32325A (es) Inhibidores de ns3 proteasa del vhc
EA201171174A1 (ru) Ингибиторы репликации вируса гепатита c
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
ECSP10010210A (es) Compuestos nucleósidos antivirales
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
BRPI1016167A2 (pt) compostos heterocíclicos antivirais.
MX2011012541A (es) Compuestos heterociclicos antivirales.
UY30545A1 (es) Derivados sustituidos del acido acilamino-benzoico, composiciones que los contienen y aplicaciones
MX2011012240A (es) Compuestos heterociclicos antivirales.
EA201300473A1 (ru) Ингибиторы вирусной полимеразы
BR112013000245A2 (pt) compostos antivirais heterocíclicos
BR112012012085A2 (pt) compostos antivirais heterocíclicos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]